SYK happens: AstraZeneca puts fostamatinib out of its misery
This article was originally published in Scrip
Executive Summary
AstraZeneca is dropping fostamatinib, the first-in-class oral spleen tyrosine kinase (SYK) inhibitor, from development after disappointing clinical results in rheumatoid arthritis in two more Phase III trials. It is returning the rights to the compound to the originator, Rigel Pharmaceuticals, which is still contemplating its fate.